Should I Buy CTSO? CTSO 2026 Analysis

Should You Buy Cytosorbents Corp (CTSO) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

0.670

1 Day change

6.66%

52 Week Range

1.610

Analysis Updated At

2026/02/04

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Not a good buy right now for an impatient entry: the broader trend is still bearish (SMA_200 > SMA_20 > SMA_5) and there are no near-term catalysts/news to force a breakout.
Despite a mildly improving momentum read (MACD histogram slightly > 0), price is sitting essentially on the pivot (~0.677) with nearby downside to S1 (0.638) if the market weakens.
Options positioning looks call-leaning (low put/call OI), but there is effectively no options volume today, so sentiment confirmation is weak.
Intellectia Proprietary Trading Signals
AI Stock Picker: no signal on given stock today.
SwingMax: No signal on given stock recently.

Technical Analysis

Trend: Bearish structure (SMA_200 > SMA_20 > SMA_5) indicates the stock is still in a downtrend/weak regime.
Momentum: MACD histogram at 0.000142 is above zero and expanding, suggesting early stabilization/attempted turn, but not yet a confirmed uptrend.
RSI(6): 48.67 (neutral) → no oversold bounce signal and no strong momentum.
Key levels: Pivot 0.677 (price ~0.675). Upside levels: R1 0.715, R2 0.738. Downside risk levels: S1 0.638, S2 0.615.
Pattern-based odds: Model suggests a modest positive drift (70% chance of +1.45% next day; +2.6% next week; +7.29% next month), but this conflicts with the still-bearish moving-average stack—implying choppy mean-reversion rather than a clean trend.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Open interest: Calls 155 vs Puts 60 (put/call OI 0.39) → positioning skews bullish/hedge-light.
Volume: 0 contracts traded today (put/call volume ratio 0.0) → sentiment signal is weak due to no participation.
Volatility: IV_30d 425.39% (IV percentile 90.04) → extremely elevated implied vol, typically seen in highly speculative microcaps; tends to make options expensive and signals the market is pricing large moves.
OI activity: today vs OI avg 30d ~96.85% suggests OI is present but not expanding aggressively today.

Technical Summary

Sell

Buy

Positive Catalysts

- Financial trajectory improving: Q3 2025 revenue +10.12% YoY and gross margin improved to 70.28% (+15.18% YoY), supporting a better operating profile.
- Early momentum stabilization: MACD turning positive suggests selling pressure may be fading.
- Options OI skew favors calls (put/call OI 0.39), implying more bullish positioning than bearish hedging.

Neutral/Negative Catalysts

- No recent news/events in the past week to drive an immediate re-rating or breakout.
- Technical trend remains bearish (moving averages stacked negatively), increasing risk that rallies fade.
- Analyst stance is Neutral with a reduced target, explicitly citing continued drag in Germany revenues.
- Extremely high implied volatility can coincide with unstable price action and failed breakouts.
- No supportive “smart money” momentum signals: hedge fund/insider trends are neutral; no Intellectia buy signals today.

Financial Performance

Latest quarter: 2025/Q3.
Revenue: 9.485M, up 10.12% YoY (top-line growth positive).
Net income: -3.17M (still a loss), improved 14.52% YoY (loss narrowing).
EPS: -0.05, essentially flat YoY.
Gross margin: 70.28%, up 15.18% YoY (strong improvement; favorable mix/efficiency).

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Latest update (2025-11-14): H.C. Wainwright (Sean Lee) maintained Neutral and cut price target to $0.75 from $1.00.
Rationale: estimate reductions due to a “continued drag” on Germany revenues.
Wall Street pro view (pros): improving revenue growth and materially stronger gross margin could support gradual fundamental repair.
Wall Street con view (cons): persistent losses and region-specific revenue headwinds are limiting conviction, keeping the stock in a Neutral/uncertain bucket.
Politicians/congress: No recent congress trading data available in the last 90 days.

1 Analyst Rating

Wall Street analysts forecast CTSO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CTSO is 0.75 USD with a low forecast of 0.75 USD and a high forecast of 0.75 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

0 Buy

1 Hold

0 Sell

Hold

Current: 0.630

Low

0.75

Averages

0.75

High

0.75

Current: 0.630

Low

0.75

Averages

0.75

High

0.75

H.C. Wainwright

Sean Lee

Neutral

downgrade

AI Analysis

2025-11-14

Reason

H.C. Wainwright

Sean Lee

Price Target

AI Analysis

2025-11-14

downgrade

Neutral

Reason

H.C. Wainwright analyst Sean Lee lowered the firm's price target on CytoSorbents to 75c from $1 and keeps a Neutral rating on the shares. The firm reduced estimates to reflect to the "continued drag" on the company's Germany revenues.

HC Wainwright & Co.

Sean Lee

Hold

Reiterates

2025-04-03

Reason

HC Wainwright & Co.

Sean Lee

Price Target

2025-04-03

Reiterates

Hold

Reason

CTSO Should I Buy

CTSO Should I Buy

Should You Buy Cytosorbents Corp (CTSO) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch